Front Pharmacol:黄芪散通过调节糖尿病小鼠脂肪岛轴改善2型糖尿病

2022-09-09 紫菀款冬 MedSci原创

探讨黄芪散对糖尿病小鼠的作用及其机制。

目的:肥胖2型糖尿病(T2DM)的全球发病率显著增加,胰岛素抵抗是T2DM最重要的发病机制和治疗靶点。中药方剂黄芪散(APF)出自《圣济总录》,由黄芪、葛根、桑白皮组成,在中国古代具有悠久的用于治疗糖尿病的历史。该研究旨在探讨APF对糖尿病小鼠的作用及其机制。

方法:用高脂饮食(HFD)链脲佐菌素(STZ)诱导糖尿病小鼠。检测小鼠体重及其血糖、胰岛素、瘦素和血脂的血浆水平。进行逆转录聚合酶链反应、组织学和蛋白质印迹分析,以验证APF对糖尿病小鼠的作用,并研究其潜在机制。

结果:APF可降低高血糖、高胰岛素血症和高瘦素血症,并减轻肥胖和非酒精性脂肪肝(NAFLD)的进展。然而,在瘦素缺乏的ob/ob糖尿病小鼠和STZ诱导的胰岛素缺乏的1型糖尿病小鼠中,这些作用消失。这两种激素的破坏都会消除APF的治疗效果。

此外,APF抑制PTP1B以抑制胰岛素瘦素敏感性糖异生基因PEPCK脂肪生成基因FAS的蛋白表达。

结论:APF通过调节STZ+HFD诱导的T2DM小鼠的脂肪岛轴平衡,减轻肥胖、NAFLD和T2DM。然而,APF在脂肪岛轴的具体机制尚不清楚。除脂肪岛轴外,APF还降低了ob/ob小鼠的血浆低密度脂蛋白(LDL)水平,这种效应可能导致其他疾病。需要进一步研究APF在脂肪岛轴的作用机制。

 

文献来源:

Xu S, Ye B, Li J, et al. Astragalus mongholicus powder, a traditional Chinese medicine formula ameliorate type 2 diabetes by regulating adipoinsular axis in diabetic mice. Front Pharmacol. 2022;13:973927. Published 2022 Aug 15. doi:10.3389/fphar.2022.973927

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996509, encodeId=b19819965093e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed May 24 23:03:47 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788504, encodeId=51af1e88504fe, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Oct 23 19:03:47 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908736, encodeId=c38a1908e3697, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Apr 20 16:03:47 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787829, encodeId=ff221e8782930, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 14 10:03:47 CST 2023, time=2023-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248204, encodeId=16ca124820478, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 09 21:19:30 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248175, encodeId=ece312481e53f, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:11 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248174, encodeId=242112481e41d, content=不错 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:00 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248162, encodeId=6d5b124816287, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ba5616185, createdName=ms6000000041184753, createdTime=Fri Sep 09 17:59:40 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2023-05-24 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1996509, encodeId=b19819965093e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed May 24 23:03:47 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788504, encodeId=51af1e88504fe, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Oct 23 19:03:47 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908736, encodeId=c38a1908e3697, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Apr 20 16:03:47 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787829, encodeId=ff221e8782930, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 14 10:03:47 CST 2023, time=2023-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248204, encodeId=16ca124820478, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 09 21:19:30 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248175, encodeId=ece312481e53f, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:11 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248174, encodeId=242112481e41d, content=不错 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:00 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248162, encodeId=6d5b124816287, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ba5616185, createdName=ms6000000041184753, createdTime=Fri Sep 09 17:59:40 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1996509, encodeId=b19819965093e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed May 24 23:03:47 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788504, encodeId=51af1e88504fe, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Oct 23 19:03:47 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908736, encodeId=c38a1908e3697, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Apr 20 16:03:47 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787829, encodeId=ff221e8782930, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 14 10:03:47 CST 2023, time=2023-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248204, encodeId=16ca124820478, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 09 21:19:30 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248175, encodeId=ece312481e53f, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:11 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248174, encodeId=242112481e41d, content=不错 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:00 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248162, encodeId=6d5b124816287, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ba5616185, createdName=ms6000000041184753, createdTime=Fri Sep 09 17:59:40 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1996509, encodeId=b19819965093e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed May 24 23:03:47 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788504, encodeId=51af1e88504fe, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Oct 23 19:03:47 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908736, encodeId=c38a1908e3697, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Apr 20 16:03:47 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787829, encodeId=ff221e8782930, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 14 10:03:47 CST 2023, time=2023-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248204, encodeId=16ca124820478, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 09 21:19:30 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248175, encodeId=ece312481e53f, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:11 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248174, encodeId=242112481e41d, content=不错 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:00 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248162, encodeId=6d5b124816287, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ba5616185, createdName=ms6000000041184753, createdTime=Fri Sep 09 17:59:40 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2023-04-14 jj000001
  5. [GetPortalCommentsPageByObjectIdResponse(id=1996509, encodeId=b19819965093e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed May 24 23:03:47 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788504, encodeId=51af1e88504fe, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Oct 23 19:03:47 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908736, encodeId=c38a1908e3697, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Apr 20 16:03:47 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787829, encodeId=ff221e8782930, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 14 10:03:47 CST 2023, time=2023-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248204, encodeId=16ca124820478, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 09 21:19:30 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248175, encodeId=ece312481e53f, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:11 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248174, encodeId=242112481e41d, content=不错 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:00 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248162, encodeId=6d5b124816287, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ba5616185, createdName=ms6000000041184753, createdTime=Fri Sep 09 17:59:40 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2022-09-09 医鸣惊人

    认真学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1996509, encodeId=b19819965093e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed May 24 23:03:47 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788504, encodeId=51af1e88504fe, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Oct 23 19:03:47 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908736, encodeId=c38a1908e3697, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Apr 20 16:03:47 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787829, encodeId=ff221e8782930, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 14 10:03:47 CST 2023, time=2023-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248204, encodeId=16ca124820478, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 09 21:19:30 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248175, encodeId=ece312481e53f, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:11 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248174, encodeId=242112481e41d, content=不错 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:00 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248162, encodeId=6d5b124816287, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ba5616185, createdName=ms6000000041184753, createdTime=Fri Sep 09 17:59:40 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2022-09-09 ms9000000239634123

    不错

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1996509, encodeId=b19819965093e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed May 24 23:03:47 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788504, encodeId=51af1e88504fe, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Oct 23 19:03:47 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908736, encodeId=c38a1908e3697, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Apr 20 16:03:47 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787829, encodeId=ff221e8782930, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 14 10:03:47 CST 2023, time=2023-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248204, encodeId=16ca124820478, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 09 21:19:30 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248175, encodeId=ece312481e53f, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:11 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248174, encodeId=242112481e41d, content=不错 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:00 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248162, encodeId=6d5b124816287, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ba5616185, createdName=ms6000000041184753, createdTime=Fri Sep 09 17:59:40 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2022-09-09 ms9000000239634123

    不错 学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1996509, encodeId=b19819965093e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Wed May 24 23:03:47 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788504, encodeId=51af1e88504fe, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Oct 23 19:03:47 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908736, encodeId=c38a1908e3697, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Apr 20 16:03:47 CST 2023, time=2023-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787829, encodeId=ff221e8782930, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Apr 14 10:03:47 CST 2023, time=2023-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248204, encodeId=16ca124820478, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 09 21:19:30 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248175, encodeId=ece312481e53f, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:11 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248174, encodeId=242112481e41d, content=不错 学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c406465747, createdName=ms9000000239634123, createdTime=Fri Sep 09 19:17:00 CST 2022, time=2022-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248162, encodeId=6d5b124816287, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ba5616185, createdName=ms6000000041184753, createdTime=Fri Sep 09 17:59:40 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2022-09-09 ms6000000041184753

    👍🏻

    0

相关资讯

A&R:体重指数与疼痛的关联以及炎症生物标志物在手骨关节炎患者中的中介作用

在手部骨关节炎患者中,较高的BMI与手、脚和膝盖/臀部的疼痛严重程度相关。通过瘦素测量的肥胖的全身效应在手部疼痛中起更大的中介作用。由高敏C反应蛋白测量的低度炎症可能导致超重/肥胖个体的全身疼痛。

Rheumatology:二甲双胍通过靶向软骨细胞、滑膜巨噬细胞和脂肪细胞减轻骨关节炎

探讨二甲双胍对正常饮食(ND)小鼠和高脂饮食(HFD)诱导的肥胖小鼠膝骨关节炎(OA)的治疗作用及其机制。

减肥效果胜过手术!雷公藤红素有望成为减肥中药

目前,只有西药被FDA批注可以长期用于减肥。但是西药有着诸多的副作用。目前研究者证实雷公藤红素有着非常显著的减肥效果,目前有望用于临床。

Mol Metab:瘦素通过其发热作用和稳定血清甲状腺激素水平来抵消甲状腺功能减退患者的体温过低

在维持室温的甲状腺功能低下小鼠中,高瘦素水平通过棕色脂肪组织生热和白色脂肪组织褐变引起致热效应,从而稳定体温。

Clin Respir J:AR与NAR患者的血清瘦素差异及血清瘦素的诊断价值

比较了过敏性鼻炎(AR)和非过敏性鼻炎(NAR)患者的血清瘦素水平,并评估了瘦素的诊断价值情况。

Nutr Diabetes:脂肪素:瘦素比率可作为衡量老年人脂肪组织功能障碍的一个指标

脂肪过剩的特点是脂肪因子分泌的改变,如循环瘦素浓度增加而脂肪素减少。评估这种脂肪组织(AT)功能障碍的一个新兴生物标志物是脂肪素:瘦素(AL)比率。